CYP19A1 and breast cancer: Using the unbiased approach of transcriptome sequencing and unique patient samples from the two clinical trials of preoperative neoadjuvant aromatase inhibitor treated and late-stage relapse patients, we identified 68 lncRNAs that we believe are associated with late-stage relapse breast cancer signaling and phenotypes.